Previous 10 | Next 10 |
Gainers: Navidea Biopharmaceuticals (NYSEMKT: NAVB ) +92% . More news on: Navidea Biopharmaceuticals, Inc., XpresSpa Group, Inc., Celsion Corporation, Stocks on the move, , Read more ...
Recon Technology (NASDAQ: RCON ) -38% on ~$2.1M registered direct offering . More news on: Recon Technology, Ltd., Geron Corporation, Syndax Pharmaceuticals, Inc., Stocks on the move, , Read more ...
A National Cancer Institute-conducted Phase 3 clinical trial, E2112 , evaluating Pfizer's (NYSE: PFE ) Aromasin (exemestane), with or without Syndax Pharmaceuticals' (NASDAQ: SNDX ) entinostat, in patients with HR+/HER2- breast cancer who progressed on a nonsteroidal aromatase inhibitor fa...
WALTHAM, Mass. , May 21, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) today announced receipt of the final results of E2112, the Phase 3 clinical trial conducted by ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and sponsored by the National Cancer Institute (NCI),...
WALTHAM, Mass. , May 12, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the closing of its previously announced underwr...
Biotech Pulse Source: COVID-19 image by Getty Images; edits by PrudentBiotech.com It has taken a pandemic for biotechs to take flight towards their all-time high. One of the first industry groups to recover from the virus-related selloff and be neutral for the year, biotech indexes hav...
The following slide deck was published by Syndax Pharmaceuticals, Inc. in conjunction with their 2020 Q1 earnings Read more ...
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2020 Earnings Conference Call May 7, 2020 4:30 PM ET Corporate Participants Claudia Styslinger - Argot Partners Briggs Morrison - Chief Executive Officer Rick Shea - Chief Financial Officer Michael Metzger - President and Chief Operating...
Image source: The Motley Fool. Syndax Pharmaceuticals (NASDAQ: SNDX) Q1 2020 Earnings Call May 07, 2020 , 4:30 p.m. ET Operator Continue reading
Syndax Pharmaceuticals (NASDAQ: SNDX ): Q1 GAAP EPS of -$0.56 misses by $0.05 . More news on: Syndax Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
14.37%Change Percent:
Syndax Pharmaceuticals Inc. Company Name:
SNDX Stock Symbol:
NASDAQ Market:
Syndax Pharmaceuticals Inc. Website:
Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia PR Newswire – New PDUFA action date of December 26, 2024 allows FDA additional time to complete their review – WALTHAM, Mass. , ...
Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024 PR Newswire WALTHAM, Mass. , July 25, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing...
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by the rapid growth of abnormal myeloid cells, which are immature blood cells that normally...